세계의 의료 2차 소견 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Medical Second Opinion was estimated to be worth US$ 6973 million in 2024 and is forecast to a readjusted size of US$ 17948 million by 2031 with a CAGR of 14.8% during the forecast period 2025-2031.

Medical Second Opinion refers to a professional healthcare service where a patient, after receiving an initial diagnosis or treatment recommendation, consults an independent, qualified medical expert for a reevaluation. This may include a review of diagnosis, therapeutic plan, or surgical necessity. The service is typically delivered through remote consultations, online platforms, or international collaborations, especially in cases involving critical illness, rare diseases, or complex interventions. It aims to reduce misdiagnosis, enhance treatment accuracy, and build patient confidence. With the advancement of telemedicine, global healthcare connectivity, and AI-driven diagnostics, Medical Second Opinion is emerging as a critical component in premium healthcare offerings, insurance services, and cross-border referral ecosystems.

As medical decisions become more complex, the market for Medical Second Opinion services is experiencing rapid growth. According to annual reports, global high-net-worth and middle-class populations are increasingly seeking access to premium healthcare resources, especially in oncology, cardiovascular diseases, and rare conditions where patients demand confirmation and optimized treatment plans. Insurance providers are embedding second opinion services into critical illness and health insurance products, improving customer engagement and loyalty. Governments in countries like the U.S., Germany, and Singapore have incorporated second opinions into reimbursement or legal frameworks, enhancing credibility. Meanwhile, the integration of AI-assisted diagnostics, international telemedicine platforms, and global medical expert networks has significantly improved the accessibility and accuracy of these services.

Despite growing interest, Medical Second Opinion services face systemic and operational barriers. Cross-border service delivery is complicated by diverse healthcare systems, lack of standardized medical records, and data interoperability issues. High-level medical expertise remains concentrated in a few top institutions, limiting supply-side scalability. In many regions, payment mechanisms are unclear, and insurance coverage is insufficient to support widespread adoption. Additionally, concerns about data privacy and regulatory compliance for cross-border data sharing pose legal risks. For emerging providers, building trust networks of qualified physicians, ensuring consistent service quality, and forming hospital partnerships are critical but challenging.

Driven by the rise of personalized medicine and patient empowerment, Medical Second Opinion services are evolving from a niche premium add-on to a standard component of clinical care. Integrated packages offering "diagnosis + expert review" are gaining popularity, particularly for cancers, cardiovascular, and neurological diseases. Digital health platforms and telemedicine providers are embedding second opinion modules into broader ecosystems that include AI imaging analysis, auto-structured medical records, and access to international experts. In fast-growing regions such as Asia and the Middle East, high-net-worth individuals and critical illness policyholders are fueling adoption, pushing the industry toward greater personalization, globalization, and platform-based models.

This report aims to provide a comprehensive presentation of the global market for Medical Second Opinion, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Medical Second Opinion by region & country, by Type, and by Application.

The Medical Second Opinion market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Medical Second Opinion.

Market Segmentation

By Company

• HCA Hospitals
• AXA PPP Healthcare
• Royal London Group
• Helsana Group
• Cleveland Clinic
• Amradnet
• Best Doctors
• Inova Care
• Toranomon Hospital
• Keio University Hospital
• Johns Hopkins Medicine
• Penn Medicine
• Oncology International Pvt. Ltd.
• GrandOpinion
• London Pain Clinic
• Mondial Assistance
• Medisense
• Medo Asia Sdn. Bhd.

Segment by Type

• Hospitals
• Medical Second Opinion Providing Companies
• Health Insurance Companies

Segment by Application

• Cancer
• Diabetes
• Cardiac Disorders
• Neurological Disorders
• Ocular Disorders
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Medical Second Opinion company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Medical Second Opinion in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Medical Second Opinion in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Medical Second Opinion Product Introduction
• 1.2 Global Medical Second Opinion Market Size Forecast (2020-2031)
• 1.3 Medical Second Opinion Market Trends & Drivers
  • 1.3.1 Medical Second Opinion Industry Trends
  • 1.3.2 Medical Second Opinion Market Drivers & Opportunity
  • 1.3.3 Medical Second Opinion Market Challenges
  • 1.3.4 Medical Second Opinion Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Medical Second Opinion Players Revenue Ranking (2024)
• 2.2 Global Medical Second Opinion Revenue by Company (2020-2025)
• 2.3 Key Companies Medical Second Opinion Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Medical Second Opinion Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Medical Second Opinion
• 2.6 Medical Second Opinion Market Competitive Analysis
  • 2.6.1 Medical Second Opinion Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Medical Second Opinion Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Medical Second Opinion as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Hospitals
  • 3.1.2 Medical Second Opinion Providing Companies
  • 3.1.3 Health Insurance Companies
• 3.2 Global Medical Second Opinion Sales Value by Type
  • 3.2.1 Global Medical Second Opinion Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Medical Second Opinion Sales Value, by Type (2020-2031)
  • 3.2.3 Global Medical Second Opinion Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Cancer
  • 4.1.2 Diabetes
  • 4.1.3 Cardiac Disorders
  • 4.1.4 Neurological Disorders
  • 4.1.5 Ocular Disorders
  • 4.1.6 Others
• 4.2 Global Medical Second Opinion Sales Value by Application
  • 4.2.1 Global Medical Second Opinion Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Medical Second Opinion Sales Value, by Application (2020-2031)
  • 4.2.3 Global Medical Second Opinion Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Medical Second Opinion Sales Value by Region
  • 5.1.1 Global Medical Second Opinion Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Medical Second Opinion Sales Value by Region (2020-2025)
  • 5.1.3 Global Medical Second Opinion Sales Value by Region (2026-2031)
  • 5.1.4 Global Medical Second Opinion Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Medical Second Opinion Sales Value, 2020-2031
  • 5.2.2 North America Medical Second Opinion Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Medical Second Opinion Sales Value, 2020-2031
  • 5.3.2 Europe Medical Second Opinion Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Medical Second Opinion Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Medical Second Opinion Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Medical Second Opinion Sales Value, 2020-2031
  • 5.5.2 South America Medical Second Opinion Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Medical Second Opinion Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Medical Second Opinion Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Medical Second Opinion Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Medical Second Opinion Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Medical Second Opinion Sales Value, 2020-2031
  • 6.3.2 United States Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Medical Second Opinion Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Medical Second Opinion Sales Value, 2020-2031
  • 6.4.2 Europe Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Medical Second Opinion Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Medical Second Opinion Sales Value, 2020-2031
  • 6.5.2 China Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Medical Second Opinion Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Medical Second Opinion Sales Value, 2020-2031
  • 6.6.2 Japan Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Medical Second Opinion Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Medical Second Opinion Sales Value, 2020-2031
  • 6.7.2 South Korea Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Medical Second Opinion Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Medical Second Opinion Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Medical Second Opinion Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Medical Second Opinion Sales Value, 2020-2031
  • 6.9.2 India Medical Second Opinion Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Medical Second Opinion Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 HCA Hospitals
  • 7.1.1 HCA Hospitals Profile
  • 7.1.2 HCA Hospitals Main Business
  • 7.1.3 HCA Hospitals Medical Second Opinion Products, Services and Solutions
  • 7.1.4 HCA Hospitals Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.1.5 HCA Hospitals Recent Developments
• 7.2 AXA PPP Healthcare
  • 7.2.1 AXA PPP Healthcare Profile
  • 7.2.2 AXA PPP Healthcare Main Business
  • 7.2.3 AXA PPP Healthcare Medical Second Opinion Products, Services and Solutions
  • 7.2.4 AXA PPP Healthcare Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.2.5 AXA PPP Healthcare Recent Developments
• 7.3 Royal London Group
  • 7.3.1 Royal London Group Profile
  • 7.3.2 Royal London Group Main Business
  • 7.3.3 Royal London Group Medical Second Opinion Products, Services and Solutions
  • 7.3.4 Royal London Group Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Royal London Group Recent Developments
• 7.4 Helsana Group
  • 7.4.1 Helsana Group Profile
  • 7.4.2 Helsana Group Main Business
  • 7.4.3 Helsana Group Medical Second Opinion Products, Services and Solutions
  • 7.4.4 Helsana Group Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Helsana Group Recent Developments
• 7.5 Cleveland Clinic
  • 7.5.1 Cleveland Clinic Profile
  • 7.5.2 Cleveland Clinic Main Business
  • 7.5.3 Cleveland Clinic Medical Second Opinion Products, Services and Solutions
  • 7.5.4 Cleveland Clinic Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Cleveland Clinic Recent Developments
• 7.6 Amradnet
  • 7.6.1 Amradnet Profile
  • 7.6.2 Amradnet Main Business
  • 7.6.3 Amradnet Medical Second Opinion Products, Services and Solutions
  • 7.6.4 Amradnet Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Amradnet Recent Developments
• 7.7 Best Doctors
  • 7.7.1 Best Doctors Profile
  • 7.7.2 Best Doctors Main Business
  • 7.7.3 Best Doctors Medical Second Opinion Products, Services and Solutions
  • 7.7.4 Best Doctors Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Best Doctors Recent Developments
• 7.8 Inova Care
  • 7.8.1 Inova Care Profile
  • 7.8.2 Inova Care Main Business
  • 7.8.3 Inova Care Medical Second Opinion Products, Services and Solutions
  • 7.8.4 Inova Care Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Inova Care Recent Developments
• 7.9 Toranomon Hospital
  • 7.9.1 Toranomon Hospital Profile
  • 7.9.2 Toranomon Hospital Main Business
  • 7.9.3 Toranomon Hospital Medical Second Opinion Products, Services and Solutions
  • 7.9.4 Toranomon Hospital Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Toranomon Hospital Recent Developments
• 7.10 Keio University Hospital
  • 7.10.1 Keio University Hospital Profile
  • 7.10.2 Keio University Hospital Main Business
  • 7.10.3 Keio University Hospital Medical Second Opinion Products, Services and Solutions
  • 7.10.4 Keio University Hospital Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Keio University Hospital Recent Developments
• 7.11 Johns Hopkins Medicine
  • 7.11.1 Johns Hopkins Medicine Profile
  • 7.11.2 Johns Hopkins Medicine Main Business
  • 7.11.3 Johns Hopkins Medicine Medical Second Opinion Products, Services and Solutions
  • 7.11.4 Johns Hopkins Medicine Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Johns Hopkins Medicine Recent Developments
• 7.12 Penn Medicine
  • 7.12.1 Penn Medicine Profile
  • 7.12.2 Penn Medicine Main Business
  • 7.12.3 Penn Medicine Medical Second Opinion Products, Services and Solutions
  • 7.12.4 Penn Medicine Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Penn Medicine Recent Developments
• 7.13 Oncology International Pvt. Ltd.
  • 7.13.1 Oncology International Pvt. Ltd. Profile
  • 7.13.2 Oncology International Pvt. Ltd. Main Business
  • 7.13.3 Oncology International Pvt. Ltd. Medical Second Opinion Products, Services and Solutions
  • 7.13.4 Oncology International Pvt. Ltd. Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Oncology International Pvt. Ltd. Recent Developments
• 7.14 GrandOpinion
  • 7.14.1 GrandOpinion Profile
  • 7.14.2 GrandOpinion Main Business
  • 7.14.3 GrandOpinion Medical Second Opinion Products, Services and Solutions
  • 7.14.4 GrandOpinion Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.14.5 GrandOpinion Recent Developments
• 7.15 London Pain Clinic
  • 7.15.1 London Pain Clinic Profile
  • 7.15.2 London Pain Clinic Main Business
  • 7.15.3 London Pain Clinic Medical Second Opinion Products, Services and Solutions
  • 7.15.4 London Pain Clinic Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.15.5 London Pain Clinic Recent Developments
• 7.16 Mondial Assistance
  • 7.16.1 Mondial Assistance Profile
  • 7.16.2 Mondial Assistance Main Business
  • 7.16.3 Mondial Assistance Medical Second Opinion Products, Services and Solutions
  • 7.16.4 Mondial Assistance Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.16.5 Mondial Assistance Recent Developments
• 7.17 Medisense
  • 7.17.1 Medisense Profile
  • 7.17.2 Medisense Main Business
  • 7.17.3 Medisense Medical Second Opinion Products, Services and Solutions
  • 7.17.4 Medisense Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.17.5 Medisense Recent Developments
• 7.18 Medo Asia Sdn. Bhd.
  • 7.18.1 Medo Asia Sdn. Bhd. Profile
  • 7.18.2 Medo Asia Sdn. Bhd. Main Business
  • 7.18.3 Medo Asia Sdn. Bhd. Medical Second Opinion Products, Services and Solutions
  • 7.18.4 Medo Asia Sdn. Bhd. Medical Second Opinion Revenue (US$ Million) & (2020-2025)
  • 7.18.5 Medo Asia Sdn. Bhd. Recent Developments

8 Industry Chain Analysis

• 8.1 Medical Second Opinion Industrial Chain
• 8.2 Medical Second Opinion Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Medical Second Opinion Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Medical Second Opinion Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer